by European Public Health Alliance | Sep 23, 2022 | #A2Medicines, #VaccineEquity, COVID-19, Health Inequalities
In September 2022, the European Public Health Association published a joint statement co-signed by several health NGOs, including EPHA. The purpose of this letter is to address the health emergency preparedness, learn from the pandemic, and improve the general...
by European Public Health Alliance | Aug 29, 2022 | #A2Medicines
Guest article by Robin Doeswijk and Gauthier Quinonez, European Hematology Association Plasma Shortages Plasma-derived medicinal products (PDMPs) are used to treat various rare, chronic, and potentially life-threatening conditions including immune deficiencies,...
by Rosa Castro | Jun 30, 2022 | #A2Medicines, Monkeypox, The View from EPHA, Universal Access and Affordable Medicines | Latest Developments
“With HERA up and running, the EU has significantly reinforced its capacity to respond and address new health threats decisively”. This is what Health Commissioner Stella Kyriakides said on 28 June 2022 when she announced that the first batch of monkeypox vaccines...
by European Public Health Alliance | Jun 30, 2022 | #A2Medicines, Universal Access and Affordable Medicines | Analysis & Opinion
Guest article Jaume Vidal, Senior Policy Advisor at Health Action International (HAI) In October 2020 in the midst of the COVID-19 pandemic, South Africa and India submitted a proposal to waiver certain dispositions of the Trade- Related aspects of Intellectual...
by European Public Health Alliance | Jun 30, 2022 | #A2Medicines, Universal Access and Affordable Medicines | Analysis & Opinion
Guest article by Ancel·la Santos, Senior Health Policy Officer, The European Consumer Organisation (BEUC) To ensure recovery when facing health issues and a better quality of life among European citizens, it is essential that people get timely access to medicines and...
by European Public Health Alliance | Jun 30, 2022 | #A2Medicines, Universal Access and Affordable Medicines | Analysis & Opinion
Guest article by Charlotte Roffiaen, European Policy Advisor at France Assos Santé For many years, the increasing prices of innovative medicines have focused the attention of the European public health community. Affordability issues were threatening both patient...
